. RATIONALE: Mouse allergen reduction is associated with improvements in asthma among sensitized and exposed children, but whether age modifies responsiveness to mouse allergen reduction is unclear. METHODS: 350 mouse-sensitized and exposed asthmatic children (5-17y) were enrolled in a clinical trial of integrated pest management+edu-cation versus education alone. Symptoms (days/2 weeks), acute visits, and mouse allergen exposure were assessed every three months. Groups were combined for analyses because there were no differences in exposure or clinical outcomes. Analyses of relationships between mouse allergen and asthma outcomes were stratified at the median age (older vs. younger (> _9 vs <9y)). Mixed-effects generalized linear models were adjusted for gender, age, race, insurance, and included interaction terms (age*-log 2 (mouse allergen level)). RESULTS: Participants were predominantly low-income and minority (78% Black, 22% Hispanic), and had uncontrolled asthma. Among older participants, each 50% reduction in mouse allergen was associated with fewer symptom-days ( . There was little effect of mouse allergen reduction on symptoms among younger participants (p-values >0.05). P-values for age*mouse allergen interactions were: maximal symptoms: 0.92, cough/ wheeze/chest tightness: 0.17, running symptoms: <0.001, cough: 0.001, and rescue medication use: 0.001. Mouse allergen reduction was not associated with acute visits, stratified by age. CONCLUSIONS: Mouse allergen reduction was associated with greater improvement in some symptoms, but not acute visits, among older mousesensitized and exposed asthmatic children, suggesting that the effectiveness of allergen reduction on symptoms may vary by age. Evidence-based guidelines support the use of asthma action plans (AAPs) for asthma self-management and education despite ongoing controversy on improving outcomes. We sought to evaluate the patient and provider characteristics associated with having an AAP. METHODS: We examined data from 28,508 de-identified patients documented in the Asthma IQ database to determine current AAP use in relationship to provider type (primary care vs. asthma specialist), patient characteristics (age, race, smoking history) and comorbid conditions (rhinosinusitis, GERD, depression and obesity). Descriptive statistics were performed and Chi-square tests used to examine associations. We determined odds ratios of current AAP use for each characteristic/ comorbidity. RESULTS: 36% of children and 34% of adults with persistent asthma had a current AAP. Patients seen by an asthma specialist were more likely to have an AAP compared to those seen by a primary care physician (Child OR: 1.7, 95% CI:1.3-2.1; Adult OR: 1.8, 95% CI: 1.5-2.4). Children with rhinosinusitis (OR: 1.3; 95% CI: 1.1-1.7; p<0.05) and African American children (OR: 1.5; 95% CI 1.1, 2.0; p<0.05) were more likely to have a current AAP. Adults that were younger (OR: 0.99; 95% CI: 0.98-0.99; p<0.05), obese (OR: 1.6; 95% CI: 1.2-2.1; p<0.05) or had depression (OR: 2.1; 95% CI: 1.2-3.6; p<0.05) were more likely to have a current AAP. CONCLUSIONS: AAPs were more commonly used by asthma specialists and prescribed to patients with characteristics that have been previously shown to be associated with poor asthma outcomes. Programs such as Asthma IQ might facilitate the appropriate use of AAP in higher risk patients.
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